Zacks Investment Research upgraded shares of Biofrontera (NASDAQ:BFRA) from a sell rating to a hold rating in a research report released on Monday morning.
According to Zacks, “Biofrontera AG is a biopharmaceutical company. It engaged in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases. The company’s products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions which can sometimes lead to skin cancer as well as the treatment of certain forms of basal cell carcinoma in the European Union. Biofrontera AG is based in Leverkusen, Germany. “
A number of other equities research analysts have also recently commented on BFRA. Benchmark initiated coverage on shares of Biofrontera in a research report on Friday, March 9th. They issued a buy rating and a $19.00 target price for the company. ValuEngine cut shares of Biofrontera from a hold rating to a sell rating in a research report on Monday, April 9th. Finally, Lake Street Capital initiated coverage on shares of Biofrontera in a research report on Wednesday, April 25th. They issued a buy rating and a $19.00 target price for the company.
Shares of Biofrontera opened at $13.25 on Monday, according to MarketBeat.com. The company has a quick ratio of 9.03, a current ratio of 9.90 and a debt-to-equity ratio of 0.58. Biofrontera has a 52 week low of $11.25 and a 52 week high of $17.98.
Biofrontera (NASDAQ:BFRA) last issued its earnings results on Monday, April 30th. The company reported ($0.09) EPS for the quarter. The business had revenue of $5.53 million during the quarter. Biofrontera had a negative net margin of 106.21% and a negative return on equity of 148.20%. analysts anticipate that Biofrontera will post -0.4 EPS for the current year.
A hedge fund recently bought a new stake in Biofrontera stock. Heartland Advisors Inc. bought a new stake in Biofrontera AG (NASDAQ:BFRA) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $1,652,000. Heartland Advisors Inc. owned about 0.45% of Biofrontera as of its most recent SEC filing. Institutional investors own 3.59% of the company’s stock.
Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.